When was Sensorion founded?

Sensorion was founded in 2009 and raised its 1st funding round 14 years after it was founded.

Where is Sensorion located?

Sensorion is headquartered in Montpellier, France.

How many employees does Sensorion have?

As of Sep 30, 2026, the latest employee count at Sensorion is 84.

Is Sensorion a funded company?

Sensorion is a funded company, having raised an undisclosed amount across 4 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Aug 03, 2023.

When was the latest funding round of Sensorion?

Sensorion's latest funding was a $***** Post IPO round on Jan 28, 2026, with participation from 5 investors.

Where does Sensorion rank among its competitors?

Sensorion ranks 11th amongst 51 active competitors, of which 19 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sensorion, which secured $95.7M in Jan, 2026.

Who are the top competitors of Sensorion?

Sensorion's top competitors include Shift Bioscience, Lyra Therapeutics and IVERIC bio. Among them, Sensorion secured the most recent funding round in January, 2026.

Sensorion - 2026 Company Profile, Funding & Competitors

Sensorion is a public company based in Montpellier (France), founded in 2009. It operates as a Provider of gene therapies for the treatment and prevention of inner ear disorders to restore hearing in patients. Sensorion has raised an undisclosed amount in funding. The company has 51 active competitors, including 19 funded and 8 that have exited. Its top competitors include companies like Shift Bioscience, Lyra Therapeutics and IVERIC bio.

Company Details

Provider of gene therapies for the treatment and prevention of inner ear disorders to restore hearing in patients. It offers deep research platform aimed at understanding the pathophysiology and causes of inner ear diseases to develop effective therapeutic solutions. It offers SENS-501 a gene therapy for severe hearing loss due to OTOF gene mutations, and GJB2-GT targeting hearing loss from mutations in the GJB2 gene.

Website: www.sensorion.com/en/
Email ID: *****@sensorion-pharma.com
Phone Number: +33 **********

Key Metrics

Founded Year

2009

Location

Montpellier, France

Stage

Public

Latest Funding Round

Post IPO, Jan 28, 2026, $*****

Investors

Redmile Group & 7 more

Ranked

11^th among 51 active competitors

Employee Count

84 as on Sep 30, 2026

Similar Companies

Shift Bioscience & 59 more

Exit Details

Public

View Sensorion's full profile

Sensorion got listed on Apr 21, 2015.

Click here to take a look at Sensorion's IPO in detail

Sensorion has raised funding over 4 rounds. Its first funding round was on Aug 03, 2023. Its latest funding round was a Post IPO round on Jan 28, 2026 for $*****. 5 investors participated in its latest round. Sensorion has 8 institutional investors.

Here is the list of recent funding rounds of Sensorion:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 28, 2026	4981817	Post IPO	1013557	6901330	9969644	2181042
Apr 08, 2024	4420778	Post IPO	2821883	1726152	3080913	Redmile Group & 2 more
Feb 09, 2024	5229203	Post IPO	7807835	3931515	7043431	7521516

Access funding benchmarks and valuations. Sign up today!

View details of Sensorion's funding rounds and investors

Sensorion's employee count trend

Sensorion has 84 employees as of Sep 26. Here is Sensorion's employee count trend over the years:

Uncover Sensorion's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sensorion include Shift Bioscience, Lyra Therapeutics and IVERIC bio. Here is the list of Top 10 competitors of Sensorion, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Shift Bioscience 2017, Cambridge (United Kingdom), Seed	Developer of drugs that reprogram mitochondrial (mtDNA) mutations	$28.6M	BGF, galloway & 17 others	59/100
2nd	Lyra Therapeutics 2005, Watertown (United States), Public	Biotechnology firm innovating localized therapies for chronic rhinosinusitis (CRS)	$110M	Perceptive Advisors, HTIF & 9 others	58/100
3rd	IVERIC bio 2007, New York City (United States), Acquired	Developer of gene therapy solutions to treat retinal diseases	$204M	Avoro Capital, Frazier Healthcare Partners ... & 3 others	56/100
4th	Spiral Therapeutics 2016, Brisbane (United States), Series B	Developer of therapeutics to treat balance disorders and hearing loss	$47.3M	Catalio Capital Management, Camden Partners ... & 14 others	55/100
5th	Frequency Therapeutics 2015, Cambridge (United States), Public	Developing regenerative therapeutic for reversing hearing loss	$136M	Taiwania Capital, Axil Capital & 21 others	55/100
6th	Sound Pharma 2002, Seattle (United States), Series B	Specialty company developing novel treatment for hearing loss	$25.2M	Cystic Fibrosis Foundation, ONR & 1 others	55/100
7th	Acousia Therapeutics 2012, Tubingen (Germany), Series C	Developer of small molecule therapeutics supporting cellular regeneration to reverse hearing loss	$14.6M	Esperante, LBBW Venture Capital & 5 others	52/100
8th	Cyrano Therapeutics 2014, Washington, DC (United States), Series B	Developer of pharmaceutical therapies for smell and taste loss	$25.9M	Lumira Ventures, Remiges Ventures & 3 others	52/100
9th	Decibel Therapeutics 2015, Cambridge (United States), Acquired	Developer of new medicines to protect, repair and restore hearing capacity	$170M	Orbimed, Early Detection Ultrasound Screening ... & 16 others	51/100
10th	Mogrify 2014, Cambridge (United Kingdom), Series A	Developer of regenerative medicine and cell therapies	$50.3M	Ahren, Parkwalk & 18 others	49/100
11th	Sensorion 2009, Montpellier (France), Public	Provider of gene therapies for the treatment and prevention of inner ear disorders to restore hearing in patients	-	Redmile Group, Sanofi & 6 others	51/100